Epigenetic therapy for solid tumors: from bench science to clinical trials

Area of Science:

• Oncology
• Cancer Epigenetics
• Molecular Biology

Background:

• The cancer epigenome exhibits global DNA methylation and chromatin alterations, including CpG island promoter hypermethylation.
• Epigenetic agents, such as DNA methyltransferase and histone deacetylase inhibitors, aim to reverse these changes by reactivating silenced tumor suppressor genes.

Purpose of the Study:

• To review the efficacy of epigenetic agents in cancer therapy.
• To explore the potential of combining epigenetic agents with other treatment modalities.
• To suggest optimal strategies for future clinical trials involving epigenetic agents.

Main Methods:

• Review of existing clinical trial data and scientific literature on epigenetic agents in cancer.
• Analysis of combination therapy outcomes involving epigenetic agents, chemotherapy, and hormonal therapy.
• Discussion of novel therapeutic strategies and trial designs for epigenetic agents.

Main Results:

• Epigenetic agents have shown limited efficacy as monotherapy in solid tumors.
• Combinations of epigenetic agents with chemotherapy, hormonal therapy, or other epigenetic agents demonstrate favorable modifier effects.
• These agents can induce phenotypic changes by reactivating epigenetically silenced tumor suppressor genes.

Conclusions:

• Epigenetic agents hold promise as combination therapy for solid tumors, rather than monotherapy.
• Future research should focus on optimizing patient selection, drug regimens, study designs, and outcome measures.
• Unlocking the full therapeutic potential of epigenetic agents requires a strategic approach to clinical development.